NEW YORK, Nov. 7 – Myriad Genetics said Wednesday its fiscal first quarter revenues increased 22 percent to $13.2 million, compared with $10.8 million a year ago, boosted by strong sales of the company’s diagnostic products.

Myriad of Salt Lake City said that product revenues alone increased 81 percent in the quarter to $5.5 million. The company manufactures the BracAnalysis product for breast and ovarian cancer and the Colaris product for colon and uterine cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.